Suppr超能文献

探索玉米醇溶蛋白纳米颗粒在个性化癌症治疗中的潜力,重点介绍其各种方法、应用和挑战。

Exploring the Potential of Zein Nanoparticles in Personalised Cancer Therapy, Highlighting Their Various Methodologies, Applications and Challenges.

作者信息

Alharbi Hanan M, Alqahtani Taha, Alqalawi Nada A, Alsayegh Shayma A, Almaghrabi Basmah A, Sarkar Subham, Uti Daniel Ejim, Dhara Bikram

机构信息

Department of Pharmaceutical Sciences, Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.

Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.

出版信息

J Cell Mol Med. 2025 Aug;29(15):e70752. doi: 10.1111/jcmm.70752.

Abstract

Zein, a corn-derived prolamine protein, has become a powerful ally in the fight against cancer, particularly non-small cell lung cancer (NSCLC.) Its unique attributes, enriched by modifiable hydroxyl and amino groups, have led to the development of advanced functionalised drug delivery systems. Innovative techniques like chemical crosslinking, desolvation, dispersion and micromixing have led to the creation of zein-based nanoparticles, revolutionising cancer therapy. Central to this examination is the remarkable ability of zein NPs to enhance drug stability, optimise oral bioavailability and improve targeted drug delivery, specifically tailored to combat NSCLC. This represents not just a technological breakthrough but a paradigm shift, ushering in a new era of precise, personalised and effective cancer treatment. Zein, a hydrophobic nanoparticle, is a promising drug for cancer treatment. However, its journey to the clinic is challenging due to its hydrophobic nature and the need for advanced evaluative platforms. This review emphasises the need for rigorous research to align zein's potential with real-world applications. It offers a synthesis of methodologies, applications, and obstacles, aiming to see zein nanoparticles as a central element in cancer therapy innovations. The review encourages researchers, clinicians and industry professionals to embrace the potential of zein and promote the convergence of laboratory innovation and clinical application.

摘要

玉米醇溶蛋白是一种源自玉米的醇溶蛋白,已成为对抗癌症,尤其是非小细胞肺癌(NSCLC)的有力盟友。其独特的属性,因可修饰的羟基和氨基而得以丰富,这促使了先进的功能化药物递送系统的发展。化学交联、去溶剂化、分散和微混合等创新技术催生了基于玉米醇溶蛋白的纳米颗粒,彻底改变了癌症治疗方式。此次研究的核心在于玉米醇溶蛋白纳米颗粒具有显著能力,能够增强药物稳定性、优化口服生物利用度并改善靶向药物递送,专门针对对抗NSCLC进行了定制。这不仅代表着一项技术突破,更是一种范式转变,开启了精准、个性化且有效的癌症治疗新时代。玉米醇溶蛋白作为一种疏水性纳米颗粒,是一种很有前景的癌症治疗药物。然而,由于其疏水性以及对先进评估平台的需求,它进入临床应用的道路充满挑战。这篇综述强调了进行严谨研究以使玉米醇溶蛋白的潜力与实际应用相匹配的必要性。它综合了方法、应用和障碍,旨在将玉米醇溶蛋白纳米颗粒视为癌症治疗创新的核心要素。该综述鼓励研究人员、临床医生和行业专业人士充分利用玉米醇溶蛋白的潜力,并推动实验室创新与临床应用的融合。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验